Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back and is affecting the brain, spinal fluid, or eyes, confirmed by imaging, eye examination, or spinal fluid testing.
• People whose lymphoma also exists outside the brain and nervous system, or whose lymphoma developed from a different type (follicular lymphoma or chronic lymphocytic leukaemia), may also be considered.
• Adults aged 18 years or older.
• People whose doctor estimates they are expected to live for more than 2 months.
• People who are reasonably active and able to care for themselves (confirm with trial site what this means for your specific situation).
• People whose blood cell counts, liver function, and kidney function meet specific minimum levels set by the trial (confirm with trial site).
• People who are able to understand and sign a consent form agreeing to take part.
• People with a history of hepatitis B who have an undetectable level of virus while on treatment, if treatment is required.
• People with a history of hepatitis C who have been successfully treated and cured, or who are currently being treated and have an undetectable level of the virus.
• People who have had or currently have another type of cancer, as long as that cancer or its treatment is not likely to interfere with this trial's results or safety (confirm with trial site).
• People who are able and willing to use effective contraception during the trial, as the effects of the study drugs on an unborn baby are not yet known — this applies to women who could become pregnant and to men.
• People who have already received at least one prior treatment for their lymphoma affecting the brain, and, if the lymphoma spread to the brain from elsewhere, at least one prior treatment directed at the brain or nervous system.
• People who have previously received other treatments, including stem cell transplants, rituximab, or similar drugs, may still be considered — there is no limit on the number of prior treatments.
• People who have had a stem cell transplant, as long as they no longer have graft-versus-host disease and are no longer taking immunosuppressant medications.

Who may not be able to join:

• People who have received anti-cancer treatment within the past 2 weeks, radiation within the past 1 week, or antibody-based therapy within the past 4 weeks before the trial starts.
• People who are still experiencing significant side effects from a previous cancer treatment that have not resolved to a mild or baseline level (hair loss is an exception).
• People who are currently taking part in another clinical trial or using an experimental treatment or device.
• People who have taken part in a study involving an experimental treatment or device within the past 4 weeks.
• People with a history of HIV infection.
• People whose lymphoma in the brain or nervous system developed as a complication after an organ or stem cell transplant (a condition called post-transplant lymphoproliferative disease).
• People who have a known allergic reaction to either of the study drugs (lenalidomide or tafasitamab).
• People who are pregnant, breastfeeding, or who are able to become pregnant but are unwilling to use effective contraception during the trial.
• People who have previously received a treatment that targets a protein called CD19 on cancer cells, including a type of treatment called CAR-T cell therapy.
• People who have a serious medical condition or infection that is not under control and could put their safety at risk.

Important: Always verify eligibility with the trial site directly before applying.